{'fraction_non_alphanumeric': 0.03638644918444166, 'fraction_numerical': 0.015056461731493099, 'mean_word_length': 5.384, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma.

Fifty patients with typical infiltrating ductal adenocarcinoma of the breast were studied for amplification of the c-erb B-2 (neu/HER-2) oncogene within the tumor DNA. Amplification, ranging from 4 to greater than 50 copies per cell, was observed in 17 (34%) of the samples. The presence of c-erb B-2 gene amplification was not significantly correlated with patient survival, metastases, recurrence, or overall histologic grade. However, amplification was significantly associated with increased mitotic activity. Also, amplification of c-erb B-2 showed a significantly negative association with both progesterone and estrogen receptor presence. Progesterone receptor presence correlated significantly with survival.